Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Trastuzumab and Vinorelbine in Advanced Breast Cancer

This study has been terminated.
(Not enough confirmed responses to continue treatment.)
Sponsor:
Collaborators:
Brigham and Women's Hospital
Beth Israel Deaconess Medical Center
Massachusetts General Hospital
Genentech, Inc.
Information provided by (Responsible Party):
Ian E. Krop, MD, PhD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT01185509
First received: August 18, 2010
Last updated: August 3, 2016
Last verified: August 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: February 2015
  Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)